learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Search
forLearn
5 / 801 resultslearn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Setipiprant
learn Aminexil
learn nicotinamide
Research
5 / 1000+ resultsresearch Injectable platelet-rich fibrin promotes proliferation and trichogenic inductivityof dermal papilla cells through activating TGF-β/Smad signaling pathway
Injectable platelet-rich fibrin is better than platelet-rich plasma for promoting hair growth.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Transcriptome and proteome characterization of surface ectoderm cells differentiated from human iPSCs
Blocking TGFβ-RI signaling enhances surface ectoderm differentiation from human stem cells.
research Langerin+ Dendritic Cells in Cutaneous Fibrosis: The TGF-β1 Signaling Axis
Targeting specific cell interactions may help treat skin fibrosis.
research Synergistic larvicidal activity of Jacquinia ruscifolia flowers and Thuja orientalis strobili petroleum ether extract against Culex quinquefasciatus
Combining these plant extracts kills mosquito larvae effectively.
Community Join
5 / 1000+ resultscommunity Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community Kintor develop GT20026 Anti-Androgen receptor drug with NO SIDES
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
community Allergan recruiting for Setipiprant trial in the US
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
community Pyrilutamide available at Actifolic now
Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.